Circulating tumor cell composition and outcome in patients with solid tumors

2014 ◽  
Vol 52 (01) ◽  
pp. 74-75 ◽  
Author(s):  
Ivonne Nel ◽  
Thomas Gauler ◽  
Andreas-Claudius Hoffmann
Keyword(s):  
Tumor Cell ◽  
Solid Tumors ◽  
Circulating Tumor Cell ◽  
Cell Composition

scholarly journals Individual Profiling of Circulating Tumor Cell Composition and Therapeutic Outcome in Patients with Hepatocellular Carcinoma

2013 ◽  
Vol 6 (4) ◽  
pp. 420-428 ◽  
Author(s):  
Ivonne Nel ◽  
Hideo A. Baba ◽  
Judith Ertle ◽  
Frank Weber ◽  
Barbara Sitek ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Cell ◽  
Circulating Tumor Cell ◽  
Therapeutic Outcome ◽  
Cell Composition

scholarly journals Circulating Tumor Cell Composition in Renal Cell Carcinoma

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153018 ◽  
Author(s):  
Ivonne Nel ◽  
Thomas C. Gauler ◽  
Kira Bublitz ◽  
Lazaros Lazaridis ◽  
André Goergens ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Circulating Tumor Cell ◽  
Cell Composition

scholarly journals Antibody-modified reduced graphene oxide film for circulating tumor cell detection in early-stage prostate cancer patients

RSC Advances ◽  
2019 ◽  
Vol 9 (17) ◽  
pp. 9379-9385 ◽  
Author(s):  
Binshuai Wang ◽  
Yimeng Song ◽  
Liyuan Ge ◽  
Shudong Zhang ◽  
Lulin Ma
Keyword(s):  
Prostate Cancer ◽  
Graphene Oxide ◽  
Oxide Film ◽  
Tumor Cell ◽  
Cancer Patients ◽  
Reduced Graphene Oxide ◽  
Early Stage ◽  
Circulating Tumor Cell ◽  
Cell Detection ◽  
Reduced Graphene

We report the fabrication of an antibody-modified reduced graphene oxide film, which can be used to efficiently detect CTCs in PCa patients with PSA levels of 4–10 ng mL−1.

scholarly journals Circulating tumor cell-related transcripts in blood as prognostic biomarkers of early recurrence after liver resection for colorectal metastases

2019 ◽  
Vol 34 (3) ◽  
pp. 269-275
Author(s):  
Felice Giuliante ◽  
Elena Panettieri ◽  
Francesco Ardito ◽  
Agostino De Rose ◽  
Krizia Pocino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Tumor Cell ◽  
Carcinoembryonic Antigen ◽  
Growth Factor Receptor ◽  
Predictive Biomarker ◽  
Circulating Tumor Cell ◽  
Early Recurrence ◽  
Colorectal Metastases

Background: Several prognostic factors were proposed to improve early detection of recurrence after liver resection of metastases of colorectal cancer. Circulating tumor cell-related transcripts were evaluated in colorectal cancer patients with conflicting results. The aim of this study was to investigate usefulness of carcinoembryonic antigen CAM5, epidermal growth factor receptor, and ERCC1 transcripts in the bloodstream as predictive factors of recurrence in patients who underwent liver resection for metastases of colorectal cancer. Methods: Peripheral blood was collected from 29 patients at the time of the colorectal cancer liver metastasis resection, and from 25 normal controls. Follow-up draws (FUDs) were also performed at 30 days, and 3 and 12 months since surgery. On each sample, carcinoembryonic antigen CAM5, ERCC1, and GAPDH mRNAs were examined by quantitative reverse transcription (qRT). Results: Carcinoembryonic antigen transcript levels were linearly correlated to the number of spiked cells (qRT analytical limit = five cells). Among 29 patients (20 M/9 F; mean age 63 years (range 32–79), highly significant levels of carcinoembryonic antigen, if compared to the baseline, were detected in those relapsing after surgery ( P <0.05). The main differences were between the 1st- and 12th-month FUDs. Significantly higher levels of carcinoembryonic antigen were also detected in patients who died from disease progression during the follow-up (as evaluated at 30 days and 90 days FUDs). Conclusions: Blood carcinoembryonic antigen-mRNA absolute copy number overtime variation can represent a valid early predictor of relapse after liver resection in colorectal liver metastases patients. Prospective studies, in the context of large clinical trials, will provide further data to also qualify ERCC1 as a predictive biomarker for decisions on therapeutic strategies.

Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry

Head & Neck ◽  
2013 ◽  
Vol 36 (8) ◽  
pp. 1207-1215 ◽  
Author(s):  
Mazen A. Juratli ◽  
Mustafa Sarimollaoglu ◽  
Eric R. Siegel ◽  
Dmitry A. Nedosekin ◽  
Ekaterina I. Galanzha ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Tumor Cell ◽  
Real Time ◽  
Circulating Tumor Cell ◽  
Real Time Monitoring ◽  
Cell Release

scholarly journals Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer

2010 ◽  
Vol 134 (6) ◽  
pp. 964-969 ◽  
Author(s):  
Joseph D. Khoury ◽  
Dorothy M. Adcock ◽  
Fanny Chan ◽  
James T. Symanowski ◽  
Stefan Tiefenbacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cell ◽  
Progressive Disease ◽  
Circulating Tumor Cell ◽  
Cell Counts ◽  
D Dimer ◽  
Better Than
Sign in / Sign up

Export Citation Format

Share Document